Key investment points
This week and year to date, the medical index rose by – 2.07% and – 13.45% respectively, and the excess returns relative to the Shanghai index were 2.15% and – 0.62% respectively; This week, the share prices of medical devices, commerce and chemical drugs were relatively strong, while the share prices of medical services, biological products and traditional Chinese medicine were relatively weak; This week’s rise was among the top Changjiangrunfa Health Industry Co.Ltd(002435) (+ 61.11%), Ningbo Menovo Pharmaceutical Co.Ltd(603538) (+ 46.55%), China Meheco Group Co.Ltd(600056) (+ 42%), and the decline was among the top st national medicine (- 15.68%), Lanhai Medical Investment Co.Ltd(600896) (- 15.03%), Honz Pharmaceutical Co.Ltd(300086) (- 13.96%). Rise and fall performance characteristics: large market value companies with heavy institutional positions have weak share prices; Covid-19 treatment and covid-19 examination became hot spots in the market, led by Guangzhou Wondfo Biotech Co.Ltd(300482) , Zhejiang Orient Gene Biotech Co.Ltd(688298) and others; The performance of traditional Chinese medicine is weak and differentiated.
The antigen self-test mode is expected to be gradually implemented with large demand space: in this epidemic in Hong Kong, due to the limited PCR detection capacity, the country has started the pilot work of antigen self-test. In the future, the antigen self-test mode will be implemented nationwide with reference to the pilot results of Hong Kong and overseas experience. With the help of Hong Kong’s pilot experience, China’s scheme is expected to be promoted rapidly. On March 12, the state approved the first batch of five antigen self-test kits to complete the application change. Antigen detection is applicable to the latent and acute phase, which is of great significance for early detection. The accuracy of domestic covid-19 antibody detection has been verified overseas. In the future, covid-19 antigen self-test is expected to be widely promoted in China.
Shanghai Junshi Biosciences Co.Ltd(688180) injectable js107 was approved for clinical use, hausen pharmaceutical’s new anti-CD19 antibody drug was approved in China, China Pharmaceutical Research nip003 was approved for clinical use, and Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) tigrelol tablets were approved for registration: Shanghai Junshi Biosciences Co.Ltd(688180) injectable js107 clinical trial application was approved on March 11 for the treatment of late-stage malignant solid tumors; On March 11, the official website of nmpa announced that inelizumab injection has been approved for marketing to treat patients with optic neuromyelitis spectrum diseases; On March 9, nip003, a new generation anticoagulant of China Pharmaceutical Research Institute under China Resources pharmaceutical, recently obtained the notice of approval for drug clinical trial issued by nmpa and was approved for clinical trial for the prevention of arteriovenous thrombosis; On March 9, Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) tigrelol tablets recently received the drug registration certificate issued by nmpa for patients with acute coronary syndrome or patients with a history of myocardial infarction and at least one high-risk factor of atherosclerotic thrombosis.
Specific allocation ideas: 1) in the field of traditional Chinese medicine: it is recommended to pay attention to Zhejiang Jolly Pharmaceutical Co.Ltd(300181) , Hubei Jumpcan Pharmaceutical Co.Ltd(600566) , Chongqing Taiji Industry (Group) Co.Ltd(600129) , and recommend Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) etc; 2) CXO field of generic drugs: recommend Baicheng medicine and pay attention to Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) etc; 3) Innovative drugs and industrial chain: recommend Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Wuxi Apptec Co.Ltd(603259) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , etc; 4) Biotech innovative drugs: Yasheng medicine is recommended, and Xinda biology and kangfang biology are recommended; 5) API field: recommend Jiangxi Synergy Pharmaceutical Co.Ltd(300636) , Zhejiang Starry Pharmaceutical Co.Ltd(603520) , and pay attention to Apeloa Pharmaceutical Co.Ltd(000739) , Zhejiang Tianyu Pharmaceutical Co.Ltd(300702) , etc; 6) Vaccine field: recommend Chongqing Zhifei Biological Products Co.Ltd(300122) , Shenzhen Kangtai Biological Products Co.Ltd(300601) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , etc; 7) Growth hormone field: recommend Changchun High And New Technology Industries (Group) Inc(000661) , Anhui Anke Biotechnology (Group)Co.Ltd(300009) , etc; 8) Medical service field: recommend Aier Eye Hospital Group Co.Ltd(300015) , Topchoice Medical Co.Inc(600763) , Guizhou Xinbang Pharmaceutical Co.Ltd(002390) , etc; 8) Blood products: recommend Beijing Tiantan Biological Products Corporation Limited(600161) etc., and pay attention to Boya Bio-Pharmaceutical Group Co.Ltd(300294) ; 9) Medical and aesthetic fields: recommend Imeik Technology Development Co.Ltd(300896) , Huadong Medicine Co.Ltd(000963) , Bloomage Biotechnology Corporation Limited(688363) , Shanghai Haohai Biological Technology Co.Ltd(688366) , etc; 10) Medical devices: recommended Jiangsu Yuyue Medical Equipment And Supply Co.Ltd(002223) , Qingdao Novelbeam Technology Co.Ltd(688677) , Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , etc.
Risk tip: the progress of industrial transformation and internationalization is not as expected; R & D progress may be less than expected; The price reduction of drugs exceeded expectations; The medical insurance policy was further tightened.
